Hanwha Engine (082740.KS) is being repriced on three layers stacked on top of each other: a high-margin marine-engine earnings cycle (OPM 9.5% → 21.4% trajectory through 2027E), a 4-stroke gas-engine option for US data-center power following Wärtsilä and HD Hyundai Heavy's actual contracts, and a Hanwha Group US power package via Hanwha Energy USA / Hanwha Data Centers / Hanwha Gas Power Solutions. Full re-rating logic, P×Q×C breakdown, MW-tier earnings sensitivity, peer mapping (HD Hyundai Heavy, STX Engine), and rerating roadmap.
KOSPI jumped 2.51% April 27 as Intel's earnings beat ignited a Korean semiconductor rally. Hanwha Engine soared 16% on Q1 profit beat and data center engine orders.
Rejuran is owned and manufactured by PharmaResearch (214450.KOSDAQ), a Korean medical-aesthetics company built on its proprietary PN (Polynucleotide) / PDRN salmon-DNA platform. Rejuran is the consumer brand; PN is the platform. The company is currently the only listed public proxy for the polynucleotide skin-booster category as it expands across Southeast Asia, the Middle East, Latin America, and pursues regulated entry into China, Europe, and the US. Full ownership map, product family, financial profile, competitive landscape vs Hugel / Medytox / Galderma, and investor framework.
A practical 2026 guide for global investors on SK Hynix's HBM market share, AI memory demand, HBM3E/HBM4 transition, 72% operating margin and the key checklist for Korean AI semiconductor exposure.
Olive Young is not publicly traded. The cleanest indirect proxy is CJ Corporation (001040.KS), which owns ~51.2% of CJ Olive Young. CJ CheilJedang is a separate food entity and is not a direct K-beauty play. Better-aligned listed names: AmorePacific (090430.KS), LG H&H (051900.KS), Cosmax (192820.KS), Kolmar Korea (161890.KS), COSRX (now under Kolmar BNH). Full ownership map, IPO history, and a 5-bucket exposure framework.
How much of the KOSPI is Samsung Electronics? A practical 2026 guide for global investors explaining Samsung's index weight, KOSPI concentration, KOSPI 200, MSCI Korea, EWY and Korea ETF exposure.
Pearl Abyss closed April 27 at ₩60,200 (+5.61%), not via foreign-led mass buying, but by absorbing 75,930 shares of official short-selling, foreign-house net selling, and Kiwoom-led retail outflow with Shinhan/Korea Investment-led institutional buying. Short VWAP at ₩60,390 vs close ₩60,200 makes ₩60,400 an important next-session factor. ₩60,000 is now a first-line support candidate, not a resistance.
KOSPI surges +2.5% in a semis and power-equipment risk-on session; the PEAD screener flags Hanwha Vision, Woowon Development, Pharmicell and Bosung Powertech among the key earnings-drift names.
Part 2 of the Upstage AI thesis: how Korea's sovereign AI program, public-sector AX demand, AI voucher adoption, the Daum acquisition, B2C agents and MiniMax/Zhipu IPO peers can reshape Upstage's path to listing.
Crimson Desert's first full post-1.04.00 weekend (April 25–27 KST): average CCU -13.2% vs prior weekend, but new negative reviews -49.7%, new-review positivity +8.7pp to 87.3%, and US Steam rank improved #6.0 → #5.1. Sales run-rate decay (-5.7%) is materially shallower than CCU decay (-13.2%) — exactly the long-tail signature the platform-rerating thesis predicts.